Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Novo Nordisk Acquires 2seventy's Hemophilia A Program and Gene Editing Technology

NextEdge Admin

27 Jun 2024

2 min 24 sec

Novo Nordisk has acquired 2seventy bio's hemophilia A program and the rights to its in vivo gene editing technology in a deal valued at up to $40 million. Initially partners since 2019 on a gene editing therapy for hemophilia A, the new agreement sees 2seventy transferring this program to Novo Nordisk, effectively ending their prior collaboration. Employees from 2seventy dedicated to the hemophilia A initiative will now continue their work under Novo Nordisk's leadership.

In addition to the hemophilia A program, 2seventy will transfer its megaTAL gene editing technology to Novo Nordisk. This technology will be utilized beyond oncology and gene editing for autologous or allogeneic cell therapies of immune cells in autoimmune disease treatment. Novo Nordisk also gains a license to associated intellectual property.

The asset purchase aligns with 2seventy's recent business restructuring efforts, which included a 40% reduction in workforce to streamline operations and focus resources. This strategic move allows 2seventy to prioritize advancing Abecma (idecabtagene vicleucel), its BCMA-directed CAR T-cell therapy for multiple myeloma, in partnership with Bristol Myers Squibb.

2seventy's CEO, Chip Baird, expressed confidence in Novo Nordisk's ability to advance the hemophilia A treatment and highlighted that the divestiture supports their commitment to maximizing Abecma's impact.

For Novo Nordisk, the acquisition expands their genome editing capabilities and enables the utilization of megaTAL technology in novel therapeutic applications. Karina Thorn, corporate VP at Novo Nordisk, emphasized the strategic importance of this deal in broadening their technological portfolio.